🔬 Founding Member Rate: $4.99/mo — locks in forever.
Standard pricing coming as we grow.
Lock it in →
What Is It?
Five compounds researched for weight management, each targeting a different mechanism. Some suppress appetite. Some target fat directly. Some mimic exercise.
Compounds Covered
- Semaglutide — GLP-1 agonist. Recalibrates the hunger thermostat. ~15% weight loss. FDA-approved (Ozempic/Wegovy).
- Tirzepatide — Dual GLP-1/GIP agonist. Turns down two dials. ~22% weight loss. FDA-approved (Mounjaro/Zepbound).
- Retatrutide — Triple GLP-1/GIP/glucagon agonist. Three dials. ~28.7% weight loss. Phase 3, not yet approved.
- AOD-9604 — HGH fragment 176-191. Targets fat oxidation only, no appetite suppression. Trials failed at scale.
- MOTS-c — Mitochondrial exercise mimetic. Metabolic enhancement. Mouse data only for exogenous use.
Run the Numbers
Compare reconstitution math across weight-loss peptides — BAC water volume, syringe units, weekly totals. Free, no login required.
Open the Calculator →The Honest Part
- Only Semaglutide and Tirzepatide are FDA-approved, and they require a prescription.
- AOD-9604 trials failed — the compound didn't beat diet and exercise in larger studies.
- MOTS-c has no human trial data for weight loss.
- FDA has warned about counterfeit GLP-1 vendors.
- This is education, not a prescription.
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use the vendor-specific code shown on each card for discounts. We may earn commissions from these links.
Track Weight Loss Peptides in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →